Arbutus Biopharma
ABUS
50 hedge funds and large institutions have $133M invested in Arbutus Biopharma in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 18 increasing their positions, 16 reducing their positions, and 5 closing their positions.
156% more call options, than puts
Call options by funds: $483K | Put options by funds: $189K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
13% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 16
12% more capital invested
Capital invested by funds: $118M → $133M (+$14.7M)
1.01% more ownership
Funds ownership: 66.02% → 67.03% (+1%)
6% less funds holding
Funds holding: 53 → 50 (-3)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| 1 |
RI
RTW Investments
New York
|
+$12.9M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$457K |
| 3 |
Renaissance Technologies
New York
|
+$295K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$162K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$136K |
Top Sellers
| 1 |
AC
Armistice Capital
New York
|
-$5.2M |
| 2 |
AWG
Alpha Wave Global
New York
|
-$3.63M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.37M |
| 4 |
Goldman Sachs
New York
|
-$516K |
| 5 |
Jennison Associates
New York
|
-$455K |
ABUS Hedge Fund Activity: Q2 2017 in Review
50 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q2 2017, worth a combined $133M — up 12% from $118M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ABUS and 3 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 18 added.
The largest buyer was RTW Investments, adding an estimated $12.9M. The largest seller was Armistice Capital, exiting entirely with an estimated $5.2M sold.
- 50 institutional investors held Arbutus Biopharma (ABUS) as of Q2 2017, down from 53 in Q1 2017.
- Funds reported $133M of Arbutus Biopharma stock for Q2 2017, up 12% quarter-over-quarter.
- 3 funds opened new Arbutus Biopharma positions in Q2 2017 and 5 closed out, a net change of -2 holders.
- The largest Arbutus Biopharma buyer in Q2 2017 was RTW Investments, an estimated $12.9M added.
- The largest Arbutus Biopharma seller in Q2 2017 was Armistice Capital, an estimated $5.2M sold.
Based on aggregated 13F filings for Q2 2017.